

9 July 2015

## Director Fee Resolution at 2015 Annual Shareholder Meeting

Resolution 6 to be considered at the Annual Shareholders Meeting on 23 July, proposes that director fees be increased over a two year period as prescribed in the Resolution. Following representations from the New Zealand Shareholders Association, the Board of Comvita has agreed that the increase of director fees proposed for the 2nd year (2016-2017) would only be applied if Comvita's net profit after tax per share increases by a minimum of 20% for the year ended 31 March 2016.

# Ends #

### For further information:

Neil Craig, Chairman, 021 731 509

### Background information

#### **About Comvita** ([www.comvita.com](http://www.comvita.com))

Comvita (NZX:CVT) is a global natural health company committed to the development of innovative products, backed by ongoing investment in scientific research. We are the world leaders in Manuka (leptospermum) honey and fresh-picked Olive Leaf Extract, which are at the core of the Comvita product range.

We have approximately 50% of honey supply under direct ownership or control, with the balance of supply from long term contractual and partnership arrangements. Comvita pioneered the development and use of medical grade Manuka honey and was the first to receive FDA approval (2007). We partner with US wound care company Derma Sciences, Inc. (NASDAQ:DSCI), the global licensee for Medihoney® specialist wound care products, which are used in hospitals and medical centres around the world. Comvita's freshly picked Olive Leaf Extract is grown, harvested, extracted and bottled at the world's largest specialised olive leaf grove, with over one million olive trees.

Comvita sells into more than 18 countries through a network of our own branded retail locations, online (seven country specific e-commerce websites) and third-party outlets. We have over 500 staff located in New Zealand, Australia, Hong Kong, Japan, Taiwan, South Korea, the United Kingdom and the USA.